JMP Securities analyst David Turkaly reiterated a Hold rating on Globus Medical (GMED – Research Report) today. The company’s shares closed yesterday at $63.52.
According to TipRanks, Turkaly is a 4-star analyst with an average return of 6.4% and a 50.70% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical, AxoGen, and OrthoPediatrics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Globus Medical with a $70.25 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $84.23 and a one-year low of $52.60. Currently, Globus Medical has an average volume of 693.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Read More on GMED:
- ACADIA Pharmaceuticals (ACAD) Receives a Buy from JMP Securities
- BellRing Brands Announces Upsizing and Pricing of Secondary Equity Offering of Shares of Common Stock Held by Post
- Which 3 ARK Innovation Stocks Can Bounce the Most?
- PubMatic (PUBM) Gets a Buy from Oppenheimer
- Mizuho Securities Keeps Their Hold Rating on Corvus Pharmaceuticals (CRVS)
